465 N. HALSTEAD ST., PASADENA, CA
Termination of Collaboration Agreement with Genentech, Inc.
Announces Change to Ultomiris® Royalty Revenue Forecast
Reports Fourth Quarter and Full Year 2025 Financial Results
Highlights Corporate Priorities and 2026 Pipeline Milestones
Reports Third Quarter 2025 Financial Results
Investor Presentation
Financial Results, Press Release
Appoints Raymond Deshaies, Ph.D., to Board of Directors
FY 2024
Q3
Q2
Q1
FY 2023
Amended Quarterly Report
Amended Annual Report
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
S-8 POS